Blood filtering for shock after heart attack
Part of Heart & circulation clinical trials.
This trial tests a new blood-filtering device called Efferon CT for people with cardiogenic shock after a heart attack. The device aims to help your body recover by cleaning harmful substances from your blood, and you might join if you are diagnosed early and don't have other serious health issues.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were just diagnosed with cardiogenic shock (very low blood pressure) after a heart attack, and it's been less than 4 hours.
- Your shock is at a moderate stage (B or C on the SCAI scale) – not too mild or too severe.
- Your overall health is good enough that you can stay on the Efferon CT blood-filtering device for at least 4 hours.
- Your SOFA score (measure of organ function) is 12 or lower, meaning your organs are not failing badly.
- You do not have certain conditions like broken-heart syndrome, recent heart attack, severe kidney disease on dialysis, or cancer/autoimmune treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether filtering a protein called CRP from the blood can help people in cardiogenic shock after a heart attack. It might reduce inflammation and improve recovery.
This study looks at whether adding two simple blood test markers to a standard heart failure score can better predict recovery in people with cardiogenic shock, a condition where the heart cannot pump enough blood. The goal is to help doctors tailor treatment for each patient.
This trial tests whether using a temporary heart pump plus close monitoring improves recovery in people with severe heart failure after a heart attack, compared to standard care.
This trial tests a new heart-assist device designed to help patients whose hearts are too weak to pump blood on their own after heart surgery. The device is placed through a catheter (thin tube) and aims to improve blood flow and survival in people who don't respond to standard medications.
This trial tests a new type of cell therapy (FAP iCDC) for people who have had a severe heart attack that caused their heart to pump too weakly (cardiogenic shock). The goal is to see if this treatment can help the heart recover better after the artery has been opened.
This trial tests a new heart pump (Impella device) for people who have a severe heart attack and go into shock (very low blood pressure). It aims to see if the pump can help the heart recover better than standard care.
Hear when a new Cardiogenic Shock trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.